Theranostic PET takes on both ovarian and prostate cancer
Molecular imaging agent effectively targets multiple tumor types
2015-06-08
(Press-News.org) Baltimore, Md. (Embargoed until 12:30 p.m. EDT, June 8, 2015) - A first-in-human study revealed at the 2015 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) shows how a powerful new drug finds and attaches itself to the ovarian and prostate cancer cells for both imaging and personalized cancer treatment.
The targeted aspect of the imaging agent, called I-124 PEG-AVP0458, is a small protein (avibody) linked to polyethylene glycol (PEG) chains. The drug compound is then labeled with the radionuclide iodine-124. Drugs like PEG-AVP0458 are known as theranostic agents, because they can be used in both diagnostic and therapeutic contexts with the aid of positron emission tomography (PET). PET scanners can identify tumor sites by detecting radioactive particles that have hitched a ride with the anti-cancer antibodies following injection. A stronger radionuclide or toxin can also be attached to the avibody to destroy those tumors while protecting nearby healthy tissues.
"Avibodies are a novel, small form of antibody that still retains a high affinity for cancer antigens," said Andrew Scott, MD, lead author for the multi-site study and a researcher from the department of nuclear medicine and Centre for PET at Austin Hospital, Melbourne, Victoria, Australia. "The avibody we have developed targets prostate and ovarian cancer and has great potential as a theranostic agent for both imaging and therapy."
This study exemplifies the versatility of PEG-AVP0458 for delivering a range of radionuclides or other cancer-fighting drugs for the treatment of relapsed and metastatic ovarian and prostate cancer. Results of the study demonstrated how six patients, five men with prostate cancer and one woman with ovarian cancer, all ranging in age from 62 to 85 years of age, were imaged safely with variable doses of I-124 PEG-AVP0458. PET images highlighted areas of increased agent binding in metastatic tumors of the liver and lymph nodes within a day of injection.
This drug is still in initial phases of study. Researchers working with Avipep Pty Ltd expect clinical trials to continue over the course of the next three to five years. If approved, PEG-AVP0458 could be added to the existing arsenal for combatting prostate and ovarian cancer.
INFORMATION:
Scientific Paper 280: "Phase I Safety and Biodistribution Study of 124I-PEG-AVP0458 Diabody in Patients with TAG-72 Positive Ovarian and Prostate Cancer," A.M. Scott, F. Lee, M. Ciprotti, I. Davis, A. Weickhardt, S. Lee, Ludwig Institute, and Department of Nuclear Medicine and Centre for PET, Austin Hospital, Melbourne, Victoria, Australia; T. Akhurst, R.J. Hicks, Departments of Oncology and Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; M. Oh, P. Hudson, Avipep Pty Ltd and Victorian Cancer Biologics Consortium, Melbourne, Victoria, Australia; SNMMI's 62nd Annual Meeting, June 6-10, 2015, Baltimore, Md.
About the Society of Nuclear Medicine and Molecular Imaging
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) is an international scientific and medical organization dedicated to raising public awareness about nuclear medicine and molecular imaging, a vital element of today's medical practice that adds an additional dimension to diagnosis, changing the way common and devastating diseases are understood and treated and helping provide patients with the best health care possible.
SNMMI's 18,000 members set the standard for molecular imaging and nuclear medicine practice by creating guidelines, sharing information through journals and meetings and leading advocacy on key issues that affect molecular imaging and therapy research and practice. For more information, visit http://www.snmmi.org.
ELSE PRESS RELEASES FROM THIS DATE:
2015-06-08
Baltimore, Md. (Embargoed until 12:30 p.m. EDT, June 8, 2015) - Non-Hodgkin lymphoma (NHL), a potentially devastating cancer of the blood and immune system, can range from relatively easy to treat to very aggressive. For more aggressive cases, post-treatment surveillance with molecular imaging could mean the early start of a new, life-saving treatment, say researchers presenting during the 2015 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI).
NHL is the fifth most prevalent cancer in America, according to lead author Mehdi Taghipour, MD, ...
2015-06-08
Baltimore, Md. (embargoed until 12:30 p.m. EDT, June 8, 2015) - Research presented at the 2015 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) shows how a new molecular imaging agent finds prostate cancer that has spread to other tissues by locking in on an enzyme called prostate specific membrane antigen (PSMA), associated with prostate cancer.
"To date, conventional imaging is limited in detecting prostate cancer metastasis accurately and measurably," said Neeta Pandit-Taskar, MD, co-author of the study and a researcher at Memorial Sloan ...
2015-06-08
A recently developed tool can accurately predict the risk of death for patients within 1 year after admission to hospital using routinely collected data, reports a study in CMAJ (Canadian Medical Association Journal).
"An accurate assessment of risk of death, particularly if that risk is high, could motivate and inform discussions between patients and physicians regarding goals of care," states Dr. Carl van Walraven, a researcher at the Ottawa Hospital and the University of Ottawa, Ottawa, Ontario, who developed the tool.
Researchers in Canada and the United States ...
2015-06-08
Baltimore, Md. -- Scientists are taking medical imaging research and drug discovery to a new level by developing a molecular imaging system that combines several advanced technologies for all-in-one imaging of both tissue models and live subjects, say presenters at the 2015 annual meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI).
The preclinical and intra-vital molecular imaging system houses a window for tissue observation in addition to a larger imaging chamber. Together they are being used to peer into the microenvironment of tumors and other ...
2015-06-08
Baltimore, Md. (Embargoed until 12:30 p.m., June 8, 2015) - The origin of cancer is often obscured by metastases--tumors that have already spread to other tissues. This is especially the case for neuroendocrine tumors (NETs), a malignancy of nerve cells scattered throughout various organ systems that are sensitive to the signaling of neurotransmitters and hormones. An investigational molecular imaging technique could be the key to finding the elusive primary tumor, say presenters at the 2015 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI). ...
2015-06-08
Baltimore, Md. -- A relatively new biomarker called prostate-specific membrane antigen (PSMA) is the bullseye for three new magnetic resonance imaging (MRI) agents that bind to the protein in not only prostate cancer, but a range of tumor types, according to research unveiled at the 2015 annual meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI).
'We have shown in this proof-of-concept study that PSMA could serve as a biomarker for MR-based molecular imaging due to its high concentration within target cells, limited expression within non-targeted ...
2015-06-08
Baltimore, Md. -- Amyloid build-up is commonly talked about in relation to Alzheimer's disease, but amyloidosis can be found throughout the body. An excessive accumulation of these insoluble proteins could cause a heart attack or even death. A new molecular imaging scan of amyloid in the heart could help diagnose the problem, say researchers at the 2015 annual meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI).
The condition is called transthyretin-type (TTR) amyloidosis after the TTR gene thought to cause the over-abundance of plaque build-up. ...
2015-06-08
Baltimore, Md. -- New research presented during the 2015 annual meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) demonstrates that amyloid positron emission tomography (amyloid PET) scans of the brain provide clearer diagnosis and earlier, more effective treatment for Alzheimer's patients, when results of a more conventional PET scan remain ambiguous.
Researchers reviewed the clinical outcomes of two kinds of PET scans: a preliminary scan with a common radiotracer called fluorodeoxyglucose (FDG), which acts like glucose in the brain to capture ...
2015-06-08
Baltimore, Md. -- Fatal cardiac events are often preceded by abnormal blood clots, also called thrombosis. Scientists have now developed a molecular imaging technique that could save lives by revealing troublesome thrombi, according to a study presented at the 2015 annual meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI).
'Thrombosis is the underlying cause of deadly diseases such as stroke, pulmonary embolism, deep vein thrombosis and heart attack, which affect millions of people worldwide,' said Francesco Blasi, Ph.D., lead author of the study ...
2015-06-08
Baltimore, Md. (Embargoed until 12:30 p.m., June 8, 2015) - Neuroinflammation caused by a reactive immune system could be tripping off the neurodegeneration seen in certain dementias, multiple sclerosis, and other deadly diseases of the nervous system. A novel molecular imaging technique could be the key to understanding how best to treat these and other devastating diseases, according to a recent study presented at the 2015 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI).
At the heart of this maladaptive immune response are microglia, ...
LAST 30 PRESS RELEASES:
[Press-News.org] Theranostic PET takes on both ovarian and prostate cancer
Molecular imaging agent effectively targets multiple tumor types
